Advertisement

Topics

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION DOCETAXEL injection, for intravenous use Initial U.S. Approval: 1996 | Docetaxel [McKesson Packaging Services a business unit of McKesson Corporation] | BioPortfolio

12:36 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

The incidence of treatment-related mortality associated with docetaxel therapy is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m [see Warnings and Precautions (5.1)].

Docetaxel Injection should not be given to patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia grade 4 but did not have an increased incidence of toxic death. Bilirubin, AST or ALT, and alkaline phosphatase values should be obtained prior to each cycle of Docetaxel Injection therapy [see Warnings and Precautions (5.2)].

Docetaxel Injection therapy should not be given to patients with neutrophil counts of <1500 cells/mm . In order to monitor the occurrence of neutropenia, which may be severe and result in infection, frequent blood cell counts should be performed on all patients receiving Docetaxel Injection . [see Warnings and Precautions (5.3)].

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely fatal anaphylaxis, have been reported in patients who received a 3-day dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and administration of appropriate therapy [see Warnings and Precautions (5.4)] . Docetaxel Injection must not be given to patients who have a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80 [see Contraindications (4)] .

Severe fluid retention occurred in 6.5% (6/92) of patients despite use of a 3-day dexamethasone premedication regimen. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions (5.5)].

Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum based chemotherapy.

Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.

Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.

Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

For all indications, toxicities may warrant dosage adjustments [see Dosage and Administration (2.7)].

Administer in a facility equipped to manage possible complications (e.g. anaphylaxis).

Breast Cancer

Patients who are dosed initially at 100 mg/m and who experience either febrile neutropenia, neutrophils <500 cells/mm for more than 1 week, or severe or cumulative cutaneous reactions during Docetaxel Injection therapy should have the dosage adjusted from 100 mg/m to 75 mg/m . If the patient continues to experience these reactions, the dosage should either be decreased from 75 mg/m to 55 mg/m or the treatment should be discontinued. Conversely, patients who are dosed initially at 60 mg/m and who do not experience febrile neutropenia, neutrophils <500 cells/mm for more than 1 week, severe or cumulative cutaneous reactions, or severe peripheral neuropathy during Docetaxel Injection therapy may tolerate higher doses. Patients who develop ≥grade 3 peripheral neuropathy should have Docetaxel Injection treatment discontinued entirely.

Combination Therapy with Docetaxel Injection in the Adjuvant Treatment of Breast Cancer

Docetaxel Injection in combination with doxorubicin and cyclophosphamide should be administered when the neutrophil count is ≥1,500 cells/mm . Patients who experience febrile neutropenia should receive G-CSF in all subsequent cycles. Patients who continue to experience this reaction should remain on G-CSF and have their Docetaxel Injection dose reduced to 60 mg/m . Patients who experience grade 3 or 4 stomatitis should have their Docetaxel Injection dose decreased to 60 mg/m . Patients who experience severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during Docetaxel Injection therapy should have their dosage of Docetaxel Injection reduced from 75 mg/m to 60 mg/m . If the patient continues to experience these reactions at 60 mg/m , treatment should be discontinued.

Non-Small Cell Lung Cancer

Monotherapy with Docetaxel Injection for NSCLC treatment after failure of prior platinum-based chemotherapy

Patients who are dosed initially at 75 mg/m and who experience either febrile neutropenia, neutrophils <500 cells/mm for more than one week, severe or cumulative cutaneous reactions, or other grade 3/4 non-hematological toxicities during Docetaxel Injection treatment should have treatment withheld until resolution of the toxicity and then resumed at 55 mg/m . Patients who develop ≥grade 3 peripheral neuropathy should have Docetaxel Injection treatment discontinued entirely.

Combination therapy with Docetaxel Injection for chemotherapy-naïve NSCLC

For patients who are dosed initially at Docetaxel Injection 75 mg/m in combination with cisplatin, and whose nadir of platelet count during the previous course of therapy is <25,000 cells/mm , in patients who experience febrile neutropenia, and in patients with serious non-hematologic toxicities, the Docetaxel Injection dosage in subsequent cycles should be reduced to 65 mg/m . In patients who require a further dose reduction, a dose of 50 mg/m is recommended. For cisplatin dosage adjustments, see manufacturers' prescribing information.

Prostate Cancer

Combination therapy with Docetaxel Injection for hormone-refractory metastatic prostate cancer

Docetaxel Injection should be administered when the neutrophil count is ≥1,500 cells/mm . Patients who experience either febrile neutropenia, neutrophils < 500 cells/mm for more than one week, severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during Docetaxel Injection therapy should have the dosage of Docetaxel Injection reduced from 75 mg/m to 60 mg/m . If the patient continues to experience these reactions at 60 mg/m , the treatment should be discontinued.

Gastric or Head and Neck Cancer

Docetaxel Injection in combination with cisplatin and fluorouracil in gastric cancer or head and neck cancer

Patients treated with Docetaxel Injection in combination with cisplatin and fluorouracil must receive antiemetics and appropriate hydration according to current institutional guidelines. In both studies, G-CSF was recommended during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than 7 days. If an episode of febrile neutropenia, prolonged neutropenia or neutropenic infection occurs despite G-CSF use, the Docetaxel Injection dose should be reduced from 75 mg/m to 60 mg/m . If subsequent episodes of complicated neutropenia occur the Docetaxel Injection dose should be reduced from 60 mg/m to 45 mg/m . In case of grade 4 thrombocytopenia the Docetaxel Injection dose should be reduced from 75 mg/m to 60 mg/m . Patients should not be retreated with subsequent cycles of Docetaxel Injection until neutrophils recover to a level >1,500 cells/mm and platelets recover to a level >100,000 cells/mm . Discontinue treatment if these toxicities persist. [see Warnings and Precautions (5.3)].

Recommended dose modifications for toxicities in patients treated with Docetaxel Injection in combination with cisplatin and fluorouracil are shown in Table 1.

Liver dysfunction:

In case of AST/ALT >2.5 to ≤5 x ULN and AP ≤2.5 x ULN, or AST/ALT >1.5 to ≤5 x ULN and AP >2.5 to ≤5 x ULN, Docetaxel Injection should be reduced by 20%.

In case of AST/ALT >5 x ULN and/or AP >5 x ULN Docetaxel Injection should be stopped.

The dose modifications for cisplatin and fluorouracil in the gastric cancer study are provided below:

Cisplatin dose modifications and delays

Peripheral neuropathy: A neurological examination should be performed before entry into the study, and then at least every 2 cycles and at the end of treatment. In the case of neurological signs or symptoms, more frequent examinations should be performed and the following dose modifications can be made according to NCIC-CTC grade:

• Grade 2: Reduce cisplatin dose by 20%.

• Grade 3: Discontinue treatment.

Ototoxicity: In the case of grade 3 toxicity, discontinue treatment.

Nephrotoxicity: In the event of a rise in serum creatinine ≥grade 2 (>1.5 x normal value) despite adequate rehydration, CrCl should be determined before each subsequent cycle and the following dose reductions should be considered (see Table 2).

For other cisplatin dosage adjustments, also refer to the manufacturers’ prescribing information.

Fluorouracil dose modifications and treatment delays

For diarrhea and stomatitis, see Table 1.

In the event of grade 2 or greater plantar-palmar toxicity, fluorouracil should be stopped until recovery. The fluorouracil dosage should be reduced by 20%.

For other >grade 3 toxicities, except alopecia and anemia, chemotherapy should be delayed (for a maximum of 2 weeks from the planned date of infusion) until resolution to grade ≤1 and then recommenced, if medically appropriate.

For other fluorouracil dosage adjustments, also refer to the manufacturers’ prescribing information.

Combination Therapy with Strong CYP3A4 inhibitors:

Table 1 - Recommended Dose Modifications for Toxicities in Patients Treated with Docetaxel Injection in Combination with Cisplatin and Fluorouracil
Toxicity Dosage adjustment
Diarrhea grade 3 First episode: reduce fluorouracil dose by 20%.
Second episode: then reduce Docetaxel Injection dose by 20%.
Diarrhea grade 4 First episode: reduce Docetaxel Injection and fluorouracil doses by 20%.
Second episode: discontinue treatment.
Stomatitis/mucositis grade 3 First episode: reduce fluorouracil dose by 20%.
Second episode: stop fluorouracil only, at all subsequent cycles.
Third episode: reduce Docetaxel Injection dose by 20%
Stomatitis/mucositis grade 4 First episode: stop fluorouracil only, at all subsequent cycles.
Second episode: reduce Docetaxel Injection dose by 20%.
Table 2 –Dose Reductions for Evaluation of Creatinine Clearance
       Creatinine clearance result before next cycle Cisplatin dose next cycle
CrCl = Creatinine clearance
CrCl ≥60 mL/min Full dose of cisplatin was given. CrCl was to be repeated before each treatment cycle.
Dose of cisplatin was reduced by 50% at subsequent cycle. If CrCl was >60 mL/min at end of cycle, full cisplatin dose was reinstituted at the next cycle.
CrCl between 40 and 59 mL/min
If no recovery was observed, then cisplatin was omitted from the next treatment cycle.
Dose of cisplatin was omitted in that treatment cycle only.

If CrCl was still <40 mL/min at the end of cycle, cisplatin was discontinued.
CrCl <40 mL/min
If CrCl was >40 and <60 mL/min at end of cycle, a 50% cisplatin dose was given at the next cycle.

If CrCl was >60 mL/min at end of cycle, full cisplatin dose was given at next cycle.

Docetaxel Injection is a cytotoxic anticancer drug. Follow special handling and disposal procedures when preparing Docetaxel Injection solutions.

If Docetaxel Injection, initial diluted solution, or final dilution for infusion should come into contact with the skin, immediately and thoroughly wash with soap and water. If Docetaxel Injection, initial diluted solution, or final dilution for infusion should come into contact with mucosa, immediately and thoroughly wash with water.

Contact of the Docetaxel Injection with plasticized PVC equipment or devices used to prepare solutions for infusion is not recommended. In order to minimize patient exposure to the plasticizer DEHP (di-2-ethylhexyl phthalate), which may be leached from PVC infusion bags or sets, the final Docetaxel Injection dilution for infusion should be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets.

Two-vial formulation (Injection with Diluent)

Docetaxel Injection requires two dilutions prior to administration. Please follow the preparation instructions provided below. Note: Both the Docetaxel Injection and the diluent vials contain an overfill to compensate for liquid loss during preparation. This overfill ensures that after dilution with the entire contents of the accompanying diluent, there is an initial diluted solution containing 10 mg/mL docetaxel.

The table below provides the fill range of the Diluent, the approximate extractable volume of Diluent when the entire contents of the diluent vial are withdrawn, and the concentration of the initial diluted solution for Docetaxel Injection 20 mg and Docetaxel Injection 80 mg (see Table 3).

One-vial formulation (Injection)

Docetaxel Injection requires NO prior dilution with a diluent and is ready to add to the infusion solution.

Please follow the preparation instructions provided below.

Table 3 – Initial Dilution of Docetaxel Injection
Product Diluent 13% (w/v) polyethylene glycol 400 in water for injection
Fill Range (mL)
Approximate extractable volume of Diluent when entire contents are withdrawn
(mL)
Concentration of the initial diluted solution (mg/mL docetaxel)
Docetaxel Injection
20 mg/0.5 mL
1.5 to 2.08 mL 1.95 mL 10 mg/mL
Docetaxel Injection
80 mg/2 mL
6 to 7.4 mL 7.2 mL 10 mg/mL

DO NOT use the two-vial formulation (Injection with diluent) with the one-vial formulation.

Two-vial formulation (Injection with Diluent)

A.Initial Diluted Solution

B.Final Dilution for Infusion

One-vial formulation (Injection)

Docetaxel Injection (20 mg/mL) requires NO prior dilution with a diluent and is ready to add to the infusion solution. Use only a 21 gauge needle to withdraw docetaxel from the vial because larger bore needles (e.g., 18 and 19 gauge) may result in stopper coring and rubber particulates.

The docetaxel dilution for infusion should be administered intravenously as a 1-hour infusion under ambient room temperature (below 25°C) and lighting conditions.

Docetaxel Injection final dilution for infusion, if stored between 2°C and 25°C (36°F and 77°F) is stable for 4 hours. Docetaxel Injection final dilution for infusion (in either 0.9% Sodium Chloride solution or 5% Dextrose solution) should be used within 4 hours (including the 1 hour intravenous administration).

Two-vial formulation (Injection with Diluent)

Docetaxel Injection 80 mg/2 mL solution in single dose vial with Diluent for Docetaxel Injection USP 80 mg. Both items are in a blister pack in one carton.

Docetaxel Injection 20 mg/0.5 mL solution in single dose vial with Diluent for Docetaxel Injection USP 20 mg. Both items are in a blister pack in one carton.

One-vial formulation (Injection in Single Dose and Multiple Dose Vials)

Docetaxel Injection: 160 mg/8 mL solution

Docetaxel Injection: 80 mg/4 mL solution

Docetaxel Injection: 20 mg/1 mL solution

Breast Cancer

Docetaxel administered at 100 mg/m was associated with deaths considered possibly or probably related to treatment in 2.0% (19/965) of metastatic breast cancer patients, both previously treated and untreated, with normal baseline liver function and in 11.5% (7/61) of patients with various tumor types who had abnormal baseline liver function (AST and/or ALT >1.5 times ULN together with AP >2.5 times ULN). Among patients dosed at 60 mg/m , mortality related to treatment occurred in 0.6% (3/481) of patients with normal liver function, and in 3 of 7 patients with abnormal liver function. Approximately half of these deaths occurred during the first cycle. Sepsis accounted for the majority of the deaths.

Non-Small Cell Lung Cancer

Docetaxel administered at a dose of 100 mg/m in patients with locally advanced or metastatic non-small cell lung cancer who had a history of prior platinum-based chemotherapy was associated with increased treatment-related mortality (14% and 5% in two randomized, controlled studies). There were 2.8% treatment-related deaths among the 176 patients treated at the 75 mg/m dose in the randomized trials. Among patients who experienced treatment-related mortality at the 75 mg/m dose level, 3 of 5 patients had an ECOG PS of 2 at study entry [see Dosage and Administration (2.2), Clinical Studies (14)].

Patients with combined abnormalities of transaminases and alkaline phosphatase should not be treated with Docetaxel Injection [see Boxed Warning, Use in Specific Populations (8.6), Clinical studies (14)].

Perform frequent peripheral blood cell counts on all patients receiving Docetaxel Injection. Patients should not be retreated with subsequent cycles of Docetaxel Injection until neutrophils recover to a level >1500 cells/mm and platelets recover to a level >100,000 cells/mm .

A 25% reduction in the dose of Docetaxel Injection is recommended during subsequent cycles following severe neutropenia (<500 cells/mm ) lasting 7 days or more, febrile neutropenia, or a grade 4 infection in a Docetaxel Injection cycle [see Dosage and Administration (2.7)].

Neutropenia (<2000 neutrophils/mm ) occurs in virtually all patients given 60 mg/m to 100 mg/m of docetaxel and grade 4 neutropenia (<500 cells/mm ) occurs in 85% of patients given 100 mg/m and 75% of patients given 60 mg/m . Frequent monitoring of blood counts is, therefore, essential so that dose can be adjusted. Docetaxel Injection should not be administered to patients with neutrophils <1500 cells/mm .

Febrile neutropenia occurred in about 12% of patients given 100 mg/m but was very uncommon in patients given 60 mg/m . Hematologic responses, febrile reactions and infections, and rates of septic death for different regimens are dose related [see Adverse Reactions (6.1), Clinical Studies (14)].

Three breast cancer patients with severe liver impairment (bilirubin >1.7 times ULN) developed fatal gastrointestinal bleeding associated with severe drug-induced thrombocytopenia. In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. Patients receiving TCF should be closely monitored during the first and subsequent cycles for febrile neutropenia and neutropenic infection [see Dosage and Administration (2.7), Adverse Reactions (6)]

Patients should be observed closely for hypersensitivity reactions, especially during the first and second infusions. Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. Severe hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and aggressive therapy. Patients with a history of severe hypersensitivity reactions should not be rechallenged with Docetaxel Injection.

Hypersensitivity reactions may occur within a few minutes following initiation of a Docetaxel Injection infusion. If minor reactions such as flushing or localized skin reactions occur, interruption of therapy is not required. All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of Docetaxel Injection [see Dosage and Administration (2.6)]

Severe fluid retention has been reported following docetaxel therapy. Patients should be premedicated with oral corticosteroids prior to each Docetaxel Injection administration to reduce the incidence and severity of fluid retention [see Dosage and Administration (2.6)]. Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions.

When fluid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg.

Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate fluid retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m . Nine of 92 patients (9.8%) of patients discontinued treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment discontinuation due to fluid retention was 1021 mg/m . Fluid retention was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of docetaxel to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s).

Treatment-related acute myeloid leukemia (AML) or myelodysplasia has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. In the adjuvant breast cancer trial (TAX316) AML occurred in 3 of 744 patients who received docetaxel, doxorubicin and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin and cyclophosphamide [see Clinical Studies (14.2)]. In TAC-treated patients, the risk of delayed myelodysplasia or myeloid leukemia requires hematological follow-up.

Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended [see Dosage and Administration (2.7)]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued docetaxel due to skin toxicity.

Severe neurosensory symptoms (e.g. paresthesia, dysesthesia, pain) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued [see Dosage and Administration (2.7)]. Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal extremity weakness occurred in 4.4% (42/965).

Cystoid macular edema (CME) has been reported in patients treated with Docetaxel Injection. Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination. If CME is diagnosed, Docetaxel Injection treatment should be discontinued and appropriate treatment initiated. Alternative non-taxane cancer treatment should be considered.

Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease.

Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content. The alcohol content in a dose of Docetaxel Injection may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. Consideration should be given to the alcohol content in Docetaxel Injection on the ability to drive or use machines immediately after the infusion.

For Two-vial formulation (Injection with Diluent) Each administration of Docetaxel Injection at 100 mg/m delivers 0.15 g/m of ethanol. For a patient with a BSA of 2.0 m , this would deliver 0.3 grams of ethanol [ see Description (11) ]. Other docetaxel products may have a different amount of alcohol.

For One-vial formulation (Injection) Each administration of Docetaxel Injection at 100 mg/m delivers 1.975 g/m of ethanol. For a patient with a BSA of 2.0 m , this would deliver 3.95 grams of ethanol [ see Description (11) ]. Other docetaxel products may have a different amount of alcohol.

Docetaxel Injection can cause fetal harm when administered to a pregnant woman. Docetaxel caused embryofetal toxicities including intrauterine mortality when administered to pregnant rats and rabbits during the period of organogenesis. Embryofetal effects in animals occurred at doses as low as 1/50 and 1/300 the recommended human dose on a body surface area basis.

There are no adequate and well-controlled studies in pregnant women using Docetaxel Injection. If Docetaxel Injection is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with Docetaxel Injection [see Use in Specific Populations (8.1)].

The most serious adverse reactions from docetaxel are:

The most common adverse reactions across all docetaxel indications are infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia. Incidence varies depending on the indication.

Adverse reactions are described according to indication. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Responding patients may not experience an improvement in performance status on therapy and may experience worsening. The relationship between changes in performance status, response to therapy, and treatment-related side effects has not been established.

Breast Cancer

Monotherapy with docetaxel for locally advanced or metastatic breast cancer after failure of prior chemotherapy

Docetaxel 100 mg/m : Adverse drug reactions occurring in at least 5% of patients are compared for three populations who received docetaxel administered at 100 mg/m as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function tests; and an additional 61 patients with various tumor types who had abnormal liver function tests at baseline. These reactions were described using COSTART terms and were considered possibly or probably related to docetaxel. At least 95% of these patients did not receive hematopoietic support. The safety profile is generally similar in patients receiving docetaxel for the treatment of breast cancer and in patients with other tumor types (See Table 4).

Table 4 - Summary of Adverse Reactions in Patients Receiving Docetaxel at 100 mg/m 2
Adverse Reaction All Tumor Types
Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN
n=2045
%
All Tumor Types
Elevated LFTs Elevated Baseline LFTs: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN
n=61
%
Breast Cancer
Normal LFTs
n=965
%
Hematologic
Neutropenia
  <2000 cells/mm 3 96 96 99
  <500 cells/mm 3 75 88 86
Leukopenia
  <4000 cells/mm 3 96 98 99
  <1000 cells/mm 3 32 47 44
Thrombocytopenia
  <100,000 cells/mm 3 8 25 9
Anemia
  <11 g/dL 90 92 94
  <8 g/dL 9 31 8
Febrile Neutropenia Febrile Neutropenia: ANC grade 4 with fever >38°C with intravenous antibiotics and/or hospitalization 11 26 12
Septic Death 2 5 1
Non-Septic Death 1 7 1
Infections
  Any 22 33 22
  Severe 6 16 6
Fever in Absence of Infection
  Any 31 41 35
  Severe 2 8 2
Hypersensitivity Reactions
Regardless of Premedication
  Any 21 20 18
  Severe 4 10 3
With 3-day Premedication n=92 n=3 n=92
  Any 15 33 15
  Severe 2 0 2
Fluid Retention
Regardless of Premedication
  Any 47 39 60
  Severe 7 8 9
With 3-day Premedication n=92 n=3 n=92
  Any 64 67 64
  Severe 7 33 7
Neurosensory
  Any 49 34 58
  Severe 4 0 6
Cutaneous
  Any 48 54 47
  Severe 5 10 5
Nail Changes
  Any 31 23 41
  Severe 3 5 4
Gastrointestinal
Nausea 39 38 42
Vomiting 22 23 23
Diarrhea 39 33 43
  Severe 5 5 6
Stomatitis
  Any 42 49 52
  Severe 6 13 7
Alopecia 76 62 74
Asthenia
  Any 62 53 66
  Severe 13 25 15
Myalgia
  Any 19 16 21
  Severe 2 2 2
Arthralgia 9 7 8
Infusion Site Reactions 4 3 4

Hematologic Reactions

Reversible marrow suppression was the major dose-limiting toxicity of docetaxel [see Warnings and Precautions (5.3)]. The median time to nadir was 7 days, while the median duration of severe neutropenia (<500 cells/mm ) was 7 days. Among 2045 patients with solid tumors and normal baseline LFTs, severe neutropenia occurred in 75.4% and lasted for more than 7 days in 2.9% of cycles.

Febrile neutropenia (<500 cells/mm with fever >38°C with intravenous antibiotics and/or hospitalization) occurred in 11% of patients with solid tumors, in 12.3% of patients with metastatic breast cancer, and in 9.8% of 92 breast cancer patients premedicated with 3-day corticosteroids.

Severe infectious episodes occurred in 6.1% of patients with solid tumors, in 6.4% of patients with metastatic breast cancer, and in 5.4% of 92 breast cancer patients premedicated with 3-day corticosteroids. Thrombocytopenia (<100,000 cells/mm3) associated with fatal gastrointestinal hemorrhage has been reported.

Hypersensitivity Reactions

Severe hypersensitivity reactions have been reported [see Boxed Warning, Warnings and Precautions (5.4)] . Minor events, including flushing, rash with or without pruritus, chest tightness, back pain, dyspnea, drug fever, or chills, have been reported and resolved after discontinuing the infusion and instituting appropriate therapy.

Fluid Retention

Fluid retention can occur with the use of docetaxel [see Boxed Warning, Dosage and Administration (2.6), Warnings and Precautions (5.5)].

Cutaneous Reactions

Severe skin toxicity is discussed elsewhere in the label [see Warnings and Precautions (5.7)]. Reversible cutaneous reactions characterized by a rash including localized eruptions, mainly on the feet and/or hands, but also on the arms, face, or thorax, usually associated with pruritus, have been observed. Eruptions generally occurred within 1 week after docetaxel infusion, recovered before the next infusion, and were not disabling.

Severe nail disorders were characterized by hypo- or hyperpigmentation, and occasionally by onycholysis (in 0.8% of patients with solid tumors) and pain.

Neurologic Reactions

Neurologic reactions are discussed elsewhere in the label [see Warnings and Precautions (5.8) ].

Gastrointestinal Reactions

Nausea, vomiting, and diarrhea were generally mild to moderate. Severe reactions occurred in 3 to 5% of patients with solid tumors and to a similar extent among metastatic breast cancer patients. The incidence of severe reactions was 1% or less for the 92 breast cancer patients premedicated with 3-day corticosteroids.

Severe stomatitis occurred in 5.5% of patients with solid tumors, in 7.4% of patients with metastatic breast cancer, and in 1.1% of the 92 breast cancer patients premedicated with 3-day corticosteroids.

Cardiovascular Reactions

Hypotension occurred in 2.8% of patients with solid tumors; 1.2% required treatment. Clinically meaningful events such as heart failure, sinus tachycardia, atrial flutter, dysrhythmia, unstable angina, pulmonary edema, and hypertension occurred rarely. Seven of 86 (8.1%) of metastatic breast cancer patients receiving docetaxel 100 mg/m in a randomized trial and who had serial left ventricular ejection fractions assessed developed deterioration of LVEF by ≥10% associated with a drop below the institutional lower limit of normal.

Infusion Site Reactions

Infusion site reactions were generally mild and consisted of hyperpigmentation, inflammation, redness or dryness of the skin, phlebitis, extravasation, or swelling of the vein.

Hepatic Reactions

In patients with normal LFTs at baseline, bilirubin values > the ULN occurred in 8.9% of patients. Increases in AST or ALT >1.5 times the ULN, or alkaline phosphatase >2.5 times ULN, were observed in 18.9% and 7.3% of patients, respectively. While on docetaxel, increases in AST and/or ALT >1.5 times ULN concomitant with alkaline phosphatase >2.5 times ULN occurred in 4.3% of patients with normal LFTs at baseline. Whether these changes were related to the drug or underlying disease has not been established.

Hematologic and other toxicity is increased at higher doses and in patients with elevated baseline liver function tests (LFTs). In the following tables, adverse drug reactions are compared for three populations: 730 patients with normal LFTs given docetaxel at 100 mg/m in the randomized and single arm studies of metastatic breast cancer after failure of previous chemotherapy; 18 patients in these studies who had abnormal baseline LFTs (defined as AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN); and 174 patients in Japanese studies given docetaxel at 60 mg/m who had normal LFTs (see Tables 5 and 6).

In the three-arm monotherapy trial, TAX313, which compared docetaxel 60 mg/m , 75 mg/m and 100 mg/m in advanced breast cancer, grade 3/4 or severe adverse reactions occurred in 49.0% of patients treated with docetaxel 60 mg/m compared to 55.3% and 65.9% treated with 75 mg/m and 100 mg/m respectively. Discontinuation due to adverse reactions was reported in 5.3% of patients treated with 60 mg/m vs. 6.9% and 16.5% for patients treated at 75 mg/m and 100 mg/m respectively. Deaths within 30 days of last treatment occurred in 4.0% of patients treated with 60 mg/m compared to 5.3% and 1.6% for patients treated at 75 mg/m and 100 mg/m respectively.

Table 5 - Hematologic Adverse Reactions in Breast Cancer Patients Previously Treated with Chemotherapy Treated at Docetaxel 100 mg/m 2 with Normal or Elevated Liver Function Tests or 60 mg/m 2 with Normal Liver Function Tests
Docetaxel
100 mg/m 2
Docetaxel
60 mg/m 2
Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN Elevated LFTs Elevated Baseline LFTs: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN Normal LFTs
Adverse Reaction n=730 n=18 n=174
% % %
Neutropenia
  Any <2000 cells/mm 3 98 100 95
  Grade 4 <500 cells/mm 3 84 94 75
Thrombocytopenia
  Any <100,000 cells/mm 3 11 44 14
  Grade 4 <20,000 cells/mm 3 1 17 1
Anemia   (<11 g/dL) 95 94 65
Infection Incidence of infection requiring hospitalization and/or intravenous antibiotics was 8.5% (n=62) among the 730 patients with normal LFTs at baseline; 7 patients had concurrent grade 3 neutropenia, and 46 patients had grade 4 neutropenia.
  Any 23 39 1
  Grade 3 and 4 7 33 0
Febrile Neutropenia Febrile Neutropenia: For 100 mg/m 2, ANC grade 4 and fever >38°C with intravenous antibiotics and/or hospitalization; for 60 mg/m 2, ANC grade 3/4 and fever >38.1°C
  By Patient 12 33 0
  By Course 2 9 0
Septic Death 2 6 1
Non-Septic Death 1 11 0
Docetaxel
100 mg/m 2
Docetaxel
60 mg/m 2
Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN Elevated LFTs Elevated Baseline Liver Function: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN Normal LFTs
Adverse Reaction n=730 n=18 n=174
% % %
NA = not available
Acute Hypersensitivity
  Reaction Regardless of Premedication
    Any 13 6 1
    Severe 1 0 0
Fluid Retention Fluid Retention includes (by COSTART): edema (peripheral, localized, generalized, lymphedema, pulmonary edema, and edema otherwise not specified) and effusion (pleural, pericardial, and ascites); no premedication given with the 60 mg/m 2 dose
  Regardless of Premedication
    Any 56 61 13
    Severe 8 17 0
Neurosensory
    Any 57 50 20
    Severe 6 0 0
Myalgia 23 33 3
Cutaneous
    Any 45 61 31
    Severe 5 17 0
Asthenia
    Any 65 44 66
    Severe 17 22 0
Diarrhea
    Any 42 28 NA
    Severe 6 11
Stomatitis
    Any 53 67 19
    Severe 8 39 1

Combination therapy with docetaxel in the adjuvant treatment of breast cancer

The following table presents treatment emergent adverse reactions observed in 744 patients, who were treated with docetaxel 75 mg/m every 3 weeks in combination with doxorubicin and cyclophosphamide (see Table 7).

Of the 744 patients treated with TAC, 36.3% experienced severe treatment emergent adverse reactions compared to 26.6% of the 736 patients treated with FAC. Dose reductions due to hematologic toxicity occurred in 1% of cycles in the TAC arm versus 0.1% of cycles in the FAC arm. Six percent of patients treated with TAC discontinued treatment due to adverse reactions, compared to 1.1% treated with FAC; fever in the absence of infection and allergy being the most common reasons for withdrawal among TAC-treated patients. Two patients died in each arm within 30 days of their last study treatment; 1 death per arm was attributed to study drugs.

Table 7- Clinically Important Treatment Emergent Adverse Reactions Regardless of Causal Relationship in Patients Receiving Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAX316).
Docetaxel 75 mg/m 2+ Doxorubicin 50 mg/m 2+ Cyclophosphamide 500 mg/m 2 (TAC)
n=744
%
Fluorouracil 500 mg/m 2+
Doxorubicin 50 mg/m 2+ Cyclophosphamide 500 mg/m 2 (FAC)
n=736
%
Adverse Reaction Any Grade 3/4 Any Grade 3/4
Anemia 92 4 72 2
Neutropenia 71 66 82 49
Fever in absence of infection 47 1 17 0
Infection 39 4 36 2
Thrombocytopenia 39 2 28 1
Febrile neutropenia 25 N/A 3 N/A
Neutropenic infection 12 N/A 6 N/A
Hypersensitivity reactions 13 1 4 0
Lymphedema 4 0 1 0
Fluid Retention COSTART term and grading system for events related to treatment. 35 1 15 0
Peripheral edema 27 0 7 0
Weight gain 13 0 9 0
Neuropathy sensory 26 0 10 0
Neuro-cortical 5 1 6 1
Neuropathy motor 4 0 2 0
Neuro-cerebellar 2 0 2 0
Syncope 2 1 1 0
Alopecia 98 N/A 97 N/A
Skin toxicity 27 1 18 0
Nail disorders 19 0 14 0
Nausea 81 5 88 10
Stomatitis 69 7 53 2
Vomiting 45 4 59 7
Diarrhea 35 4 28 2
Constipation 34 1 32 1
Taste perversion 28 1 15 0
Anorexia 22 2 18 1
Abdominal Pain 11 1 5 0
Amenorrhea 62 N/A 52 N/A
Cough 14 0 10 0
Cardiac dysrhythmias 8 0 6 0
Vasodilatation 27 1 21 1
Hypotension 2 0 1 0
Phlebitis 1 0 1 0
Asthenia 81 11 71 6
Myalgia 27 1 10 0
Arthralgia 19 1 9 0
Lacrimation disorder 11 0 7 0
Conjunctivitis 5 0 7 0

Fever and Infection

Fever in the absence of infection was seen in 46.5% of TAC-treated patients and in 17.1% of FAC-treated patients. Grade 3/4 fever in the absence of infection was seen in 1.3% and 0% of TAC- and FAC-treated patients respectively. Infection was seen in 39.4% of TAC-treated patients compared to 36.3% of FAC-treated patients. Grade 3/4 infection was seen in 3.9% and 2.2% of TAC-treated and FAC-treated patients respectively. There were no septic deaths in either treatment arm.

Gastrointestinal Reactions

In addition to gastrointestinal reactions reflected in the table above, 7 patients in the TAC arm were reported to have colitis/enteritis/large intestine perforation vs. one patient in the FAC arm. Five of the 7 TAC-treated patients required treatment discontinuation; no deaths due to these events occurred.

Cardiovascular Reactions

More cardiovascular reactions were reported in the TAC arm vs. the FAC arm; dysrhythmias, all grades (7.9% vs. 6.0%), hypotension, all grades (2.6% vs. 1.1%) and CHF (2.3% vs. 0.9%, at 70 months median follow-up). One patient in each arm died due to heart failure.

Acute Myeloid Leukemia (AML)

Treatment-related acute myeloid leukemia or myelodysplasia is known to occur in patients treated with anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. AML occurs at a higher frequency when these agents are given in combination with radiation therapy. AML occurred in the adjuvant breast cancer trial (TAX316). The cumulative risk of developing treatment-related AML at 5 years in TAX316 was 0.4% for TAC treated patients and 0.1% for FAC-treated patients. This risk of AML is comparable to the risk observed for other anthracyclines/cyclophosphamide containing adjuvant breast chemotherapy regimens.

Lung Cancer

Monotherapy with docetaxel for unresectable, locally advanced or metastatic NSCLC previously treated with platinum-based chemotherapy

Treatment emergent adverse drug reactions are shown in Table 8. Included in this table are safety data for a total of 176 patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who were treated in two randomized, controlled trials. These reactions were described using NCI Common Toxicity Criteria regardless of relationship to study treatment, except for the hematologic toxicities or where otherwise noted.

Table 8 - Treatment Emergent Adverse Reactions Regardless of Relationship to Treatment in Patients Receiving Docetaxel as Monotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN
Adverse Reaction Docetaxel
75 mg/m 2
n=176
%
Best Supportive Care
n=49
%
Vinorelbine/Ifosfamide
n=119
%
Neutropenia
  Any 84 14 83
  Grade 3/4 65 12 57
Leukopenia
  Any 84 6 89
  Grade 3/4 49 0 43
Thrombocytopenia
  Any 8 0 8
  Grade 3/4 3 0 2
Anemia
  Any 91 55 91
  Grade 3/4 9 12 14
Febrile Neutropenia Febrile Neutropenia: ANC grade 4 with fever >38°C with intravenous antibiotics and/or hospitalization 6 NA Not Applicable; 1
Infection
  Any 34 29 30
  Grade 3/4 10 6 9
Treatment Related Mortality 3 NA 3
Hypersensitivity Reactions
  Any 6 0 1
  Grade 3/4 3 0 0
Fluid Retention
  Any 3 ND Not Done 23
  Severe 3 3
Neurosensory
  Any 23 14 29
  Grade 3/4 2 6 5
Neuromotor
  Any 16 8 10
  Grade 3/4 5 6 3
Skin
  Any 20 6 17
  Grade 3/4 1 2 1
Gastrointestinal
  Nausea
    Any 34 31 31
    Grade 3/4 5 4 8
  Vomiting
    Any 22 27 22
    Grade 3/4 3 2 6
  Diarrhea
    Any 23 6 12
Grade 3/4 3 0 4
Alopecia 56 35 50
Asthenia
  Any 53 57 54
  Severe COSTART term and grading system 18 39 23
Stomatitis
  Any 26 6 8
  Grade 3/4 2 0 1
Pulmonary
  Any 41 49 45
  Grade 3/4 21 29 19
Nail Disorder
  Any 11 0 2
  Severe 1 0 0
Myalgia
  Any 6 0 3
  Severe 0 0 0
Arthralgia
  Any 3 2 2
  Severe 0 0 1
Taste Perversion
  Any 6 0 0
  Severe 1 0 0

Combination therapy with docetaxel in chemotherapy-naïve advanced unresectable or metastatic NSCLC

Table 9 presents safety data from two arms of an open label, randomized controlled trial (TAX326) that enrolled patients with unresectable stage IIIB or IV non-small cell lung cancer and no history of prior chemotherapy. Adverse reactions were described using the NCI Common Toxicity Criteria except where otherwise noted.

The second comparison in the study, vinorelbine+cisplatin versus docetaxel + carboplatin (which did not demonstrate a superior survival associated with docetaxel [see Clinical Studies (14.3)] ) demonstrated a higher incidence of thrombocytopenia, diarrhea, fluid retention, hypersensitivity reactions, skin toxicity, alopecia and nail changes on the docetaxel + carboplatin arm, while a higher incidence of anemia, neurosensory toxicity, nausea, vomiting, anorexia and asthenia was observed on the vinorelbine+cisplatin arm.

Table 9 - Adverse Reactions Regardless of Relationship to Treatment in Chemotherapy- Naïve Advanced Non-Small Cell Lung Cancer Patients Receiving Docetaxel in Combination with Cisplatin
Adverse Reaction

Docetaxel 75 mg/m 2 + Cisplatin
75 mg/m 2
n=406
%
Vinorelbine 25 mg/m 2 + Cisplatin 100 mg/m 2
n=396
%
Neutropenia
  Any 91 90
  Grade 3/4 74 78
Febrile Neutropenia 5 5
Thrombocytopenia
  Any 15 15
  Grade 3/4 3 4
Anemia
  Any 89 94
  Grade 3/4 7 25
Infection
  Any 35 37
  Grade 3/4 8 8
Fever in absence of infection
  Any 33 29
  Grade 3/4 < 1 1
Hypersensitivity Reaction Replaces NCI term "Allergy"
  Any 12 4
  Grade 3/4 3 < 1
Fluid Retention COSTART term and grading system
  Any 54 42
  All severe or life-threatening events 2 2
Pleural effusion
  Any 23 22
  All severe or life-threatening events 2 2
Peripheral edema
  Any 34 18
  All severe or life-threatening events
Weight gain <1 <1
  Any 15 9
  All severe or life-threatening events <1 <1
Neurosensory
  Any 47 42
  Grade 3/4 4 4
Neuromotor
  Any 19 17
  Grade 3/4 3 6
Skin
  Any 16 14
  Grade 3/4 <1 1
Nausea
  Any 72 76
  Grade 3/4 10 17
Vomiting
  Any 55 61
  Grade 3/4 8 16
Diarrhea
  Any 47 25
  Grade 3/4 7 3
Anorexia
  Any 42 40
  All severe or life-threatening events 5 5
Stomatitis
  Any 24 21
  Grade 3/4 2 1
Alopecia
  Any 75 42
  Grade 3 <1 0
Asthenia
  Any 74 75
  All severe or life-threatening events 12 14
Nail Disorder
  Any 14 <1
  All severe events <1 0
Myalgia
  Any 18 12
  All severe events <1 <1

Prostate Cancer

Combination therapy with docetaxel in patients with prostate cancer

The following data are based on the experience of 332 patients, who were treated with docetaxel 75 mg/m every 3 weeks in combination with prednisone 5 mg orally twice daily (see Table 10).

Table 10 - Clinically Important Treatment Emergent Adverse Reactions (Regardless of Relationship) in Patients with Prostate Cancer who Received Docetaxel in Combination with Prednisone (TAX327)
Docetaxel 75 mg/m 2 every 3 weeks + prednisone 5 mg twice daily
n=332
%
Mitoxantrone 12 mg/m 2 every 3 weeks + prednisone 5 mg twice daily
n=335
%
Adverse Reaction Any Grade 3/4 Any Grade 3/4
Anemia 67 5 58 2
Neutropenia 41 32 48 22
Thrombocytopenia 3 1 8 1
Febrile neutropenia 3 N/A 2 N/A
Infection 32 6 20 4
Epistaxis 6 0 2 0
Allergic Reactions 8 1 1 0
Fluid Retention Related to treatment 24 1 5 0
Weight Gain 8 0 3 0
Peripheral Edema 18 0 2 0
Neuropathy Sensory 30 2 7 0
Neuropathy Motor 7 2 3 1
Rash/Desquamation 6 0 3 1
Alopecia 65 N/A 13 N/A
Nail Changes 30 0 8 0
Nausea 41 3 36 2
Diarrhea 32 2 10 1
Stomatitis/Pharyngitis 20 1 8 0
Taste Disturbance 18 0 7 0
Vomiting 17 2 14 2
Anorexia 17 1 14 0
Cough 12 0 8 0
Dyspnea 15 3 9 1
Cardiac left ventricular function 10 0 22 1
Fatigue 53 5 35 5
Myalgia 15 0 13 1
Tearing 10 1 2 0
Arthralgia 8 1 5 1

Gastric Cancer

Combination therapy with docetaxel in gastric adenocarcinoma

Data in the following table are based on the experience of 221 patients with advanced gastric adenocarcinoma and no history of prior chemotherapy for advanced disease, who were treated with docetaxel 75 mg/m in combination with cisplatin and fluorouracil (see Table 11).

Table 11 - Clinically Important Treatment Emergent Adverse Reactions Regardless of Relationship to Treatment in the Gastric Cancer Study
Docetaxel 75 mg/m 2 +
cisplatin 75 mg/m 2 +
fluorouracil 750 mg/m 2
n=221
Cisplatin 100 mg/m 2 +
fluorouracil 1000 mg/m 2
n=224
Adverse Reaction Any
%
Grade 3/4
%
Any
%
Grade 3/4
%
Clinically important treatment emergent adverse reactions were determined based upon frequency, severity, and clinical impact of the adverse reaction.
Anemia 97 18 93 26
Neutropenia 96 82 83 57
Fever in the absence of infection 36 2 23 1
Thrombocytopenia 26 8 39 14
Infection 29 16 23 10
Febrile neutropenia 16 N/A 5 N/A
Neutropenic infection 16 N/A 10 N/A
Allergic reactions 10 2 6 0
Fluid retention Related to treatment 15 0 4 0
Edema 13 0 3 0
Lethargy 63 21 58 18
Neurosensory 38 8 25 3
Neuromotor 9 3 8 3
Dizziness 16 5 8 2
Alopecia 67 5 41 1
Rash/itch 12 1 9 0
Nail changes 8 0 0 0
Skin desquamation 2 0 0 0
Nausea 73 16 76 19
Vomiting 67 15 73 19
Anorexia 51 13 54 12
Stomatitis 59 21 61 27
Diarrhea 78 20 50 8
Constipation 25 2 34 3
Esophagitis/dysphagia/odynophagia 16 2 14 5
Gastrointestinal pain/cramping 11 2 7 3
Cardiac dysrhythmias 5 2 2 1
Myocardial ischemia 1 0 3 2
Tearing 8 0 2 0
Altered hearing 6 0 13 2

Head and Neck Cancer

Combination therapy with docetaxel in head and neck cancer

Table 12 summarizes the safety data obtained from patients that received induction chemotherapy with docetaxel 75 mg/m in combination with cisplatin and fluorouracil followed by radiotherapy (TAX323; 174 patients) or chemoradiotherapy (TAX324; 251 patients). The treatment regimens are described in Section 14.6.

Table 12 – Clinically Important Treatment Emergent Adverse Reactions (Regardless of Relationship) in Patients with SCCHN Receiving Induction Chemotherapy with Docetaxel in Combination with cisplatin and fluorouracil followed by radiotherapy (TAX323) or chemoradiotherapy (TAX324)
TAX323
(n=355)
TAX324
(n=494)
Docetaxel arm (n=174) Comparator arm (n=181) Docetaxel arm (n=251) Comparator arm (n=243)
Adverse Reaction
(by Body System)
Any
%
Grade
3/4
%
Any
%
Grade
3/4
%
Any
%
Grade
3/4
%
Any
%
Grade
3/4
%
Clinically important treatment emergent adverse reactions based upon frequency, severity, and clinical impact.
Neutropenia 93 76 87 53 95 84 84 56
Anemia 89 9 88 14 90 12 86 10
Thrombocytopenia 24 5 47 18 28 4 31 11
Infection 27 9 26 8 23 6 28 5
Febrile neutropenia Febrile neutropenia: grade ≥2 fever concomitant with grade 4 neutropenia requiring intravenous antibiotics and/or hospitalization. 5 N/A 2 N/A 12 N/A 7 N/A
Neutropenic infection 14 N/A 8 N/A 12 N/A 8 N/A
Cancer pain 21 5 16 3 17 9 20 11
Lethargy 41 3 38 3 61 5 56 10
Fever in the absence of infection 32 1 37 0 30 4 28 3
Myalgia 10 1 7 0 7 0 7 2
Weight loss 21 1 27 1 14 2 14 2
Allergy 6 0 3 0 2 0 0 0
Fluid retention Related to treatment. 20 0 14 1 13 1 7 2
Edema only 13 0 7 0 12 1 6 1
Weight gain only 6 0 6 0 0 0 1 0
Dizziness 2 0 5 1 16 4 15 2
Neurosensory 18 1 11 1 14 1 14 0
Altered hearing 6 0 10 3 13 1 19 3
Neuromotor 2 1 4 1 9 0 10 2
Alopecia 81 11 43 0 68 4 44 1
Rash/itch 12 0 6 0 20 0 16 1
Dry skin 6 0 2 0 5 0 3 0
Desquamation 4 1 6 0 2 0 5 0
Nausea 47 1 51 7 77 14 80 14
Stomatitis 43 4 47 11 66 21 68 27
Vomiting 26 1 39 5 56 8 63 10
Diarrhea 33 3 24 4 48 7 40 3
Constipation 17 1 16 1 27 1 38 1
Anorexia 16 1 25 3 40 12 34 12
Esophagitis/dysphagia/
Odynophagia
13 1 18 3 25 13 26 10
Taste, sense of smell altered 10 0 5 0 20 0 17 1
Gastrointestinal pain/cramping 8 1 9 1 15 5 10 2
Heartburn 6 0 6 0 13 2 13 1
Gastrointestinal bleeding 4 2 0 0 5 1 2 1
Cardiac dysrhythmia 2 2 2 1 6 3 5 3
Venous Includes superficial and deep vein thrombosis and pulmonary embolism 3 2 6 2 4 2 5 4
Ischemia myocardial 2 2 1 0 2 1 1 1
Tearing 2 0 1 0 2 0 2 0
Conjunctivitis 1 0 1 0 1 0 0.4 0

Body as a whole: diffuse pain, chest pain, radiation recall phenomenon.

Cardiovascular: atrial fibrillation, deep vein thrombosis, ECG abnormalities, thrombophlebitis, pulmonary embolism, syncope, tachycardia, myocardial infarction.

Gastrointestinal: abdominal pain, anorexia, constipation, duodenal ulcer, esophagitis, gastrointestinal hemorrhage, gastrointestinal perforation, ischemic colitis, colitis, intestinal obstruction, ileus, neutropenic enterocolitis and dehydration as a consequence to gastrointestinal events have been reported.

Hepatic: rare cases of hepatitis, sometimes fatal primarily in patients with pre-existing liver disorders, have been reported.

Neurologic: confusion, rare cases of seizures or transient loss of consciousness have been observed, sometimes appearing during the infusion of the drug.

Hearing: rare cases of ototoxicity, hearing disorders and/or hearing loss have been reported, including cases associated with other ototoxic drugs.

Respiratory: dyspnea, acute pulmonary edema, acute respiratory distress syndrome/pneumonitis, interstitial lung disease, interstitial pneumonia, respiratory failure, and pulmonary fibrosis have rarely been reported and may be associated with fatal outcome. Rare cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.

Renal: renal insufficiency and renal failure have been reported, the majority of these cases were associated with concomitant nephrotoxic drugs.

Metabolism and nutrition disorders: cases of hyponatremia have been reported.

Docetaxel is a CYP3A4 substrate. In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4.

In vivo studies showed that the exposure of docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor of CYP3A4. Protease inhibitors, particularly ritonavir, may increase the exposure of docetaxel. Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients receiving treatment with Docetaxel Injection, close monitoring for toxicity and a Docetaxel Injection dose reduction could be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided [see Dosage and Administration (2.7) and Clinical Pharmacology (12.3)].

Pregnancy Category D. [see 'Warnings and Precautions' section]

Based on its mechanism of action and findings in animals, Docetaxel Injection can cause fetal harm when administered to a pregnant woman. If Docetaxel Injection is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with Docetaxel Injection.

Docetaxel Injection can cause fetal harm when administered to a pregnant woman. Studies in both rats and rabbits at doses ≥0.3 and 0.03 mg/kg/day, respectively (about 1/50 and 1/300 the daily maximum recommended human dose on a mg/m basis), administered during the period of organogenesis, have shown that docetaxel is embryotoxic and fetotoxic (characterized by intrauterine mortality, increased resorption, reduced fetal weight, and fetal ossification delay). The doses indicated above also caused maternal toxicity.

It is not known whether docetaxel is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Docetaxel Injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

The safety and effectiveness of Docetaxel Injection in pediatric patients have not been established. The alcohol content of Docetaxel Injection should be taken into account when given to pediatric patients [ see Warnings and Precautions (5.11) ].

Non-Small Cell Lung Cancer

In a study conducted in chemotherapy-naïve patients with NSCLC (TAX326), 148 patients (36%) in the docetaxel+cisplatin group were 65 years of age or greater. There were 128 patients (32%) in the vinorelbine+cisplatin group 65 years of age or greater. In the docetaxel+cisplatin group, patients < 65 years of age had a median survival of 10.3 months (95% CI: 9.1 months, 11.8 months) and patients 65 years or older had a median survival of 12.1 months (95% CI: 9.3 months, 14 months). In patients 65 years of age or greater treated with docetaxel+cisplatin, diarrhea (55%), peripheral edema (39%) and stomatitis (28%) were observed more frequently than in the vinorelbine+cisplatin group (diarrhea 24%, peripheral edema 20%, stomatitis 20%). Patients treated with docetaxel+cisplatin who were 65 years of age or greater were more likely to experience diarrhea (55%), infections (42%), peripheral edema (39%) and stomatitis (28%) compared to patients < the age of 65 administered the same treatment (43%, 31%, 31% and 21%, respectively).

When docetaxel was combined with carboplatin for the treatment of chemotherapy-naïve, advanced non-small cell lung carcinoma, patients 65 years of age or greater (28%) experienced higher frequency of infection compared to similar patients treated with docetaxel+cisplatin, and a higher frequency of diarrhea, infection and peripheral edema than elderly patients treated with vinorelbine+cisplatin.

Prostate Cancer

Of the 333 patients treated with docetaxel every three weeks plus prednisone in the prostate cancer study (TAX327), 209 patients were 65 years of age or greater and 68 patients were older than 75 years. In patients treated with docetaxel every three weeks, the following treatment emergent adverse reactions occurred at rates ≥10% higher in patients 65 years of age or greater compared to younger patients: anemia (71% vs. 59%), infection (37% vs. 24%), nail changes (34% vs. 23%), anorexia (21% vs. 10%), weight loss (15% vs. 5%) respectively.

Breast Cancer

In the adjuvant breast cancer trial (TAX316), docetaxel in combination with doxorubicin and cyclophosphamide was administered to 744 patients of whom 48 (6%) were 65 years of age or greater. The number of elderly patients who received this regimen was not sufficient to determine whether there were differences in safety and efficacy between elderly and younger patients.

Gastric Cancer

Among the 221 patients treated with docetaxel in combination with cisplatin and fluorouracil in the gastric cancer study, 54 were 65 years of age or older and 2 patients were older than 75 years. In this study, the number of patients who were 65 years of age or older was insufficient to determine whether they respond differently from younger patients. However, the incidence of serious adverse reactions was higher in the elderly patients compared to younger patients. The incidence of the following adverse reactions (all grades, regardless of relationship): lethargy, stomatitis, diarrhea, dizziness, edema, febrile neutropenia/neutropenic infection occurred at rates ≥ 10% higher in patients who were 65 years of age or older compared to younger patients. Elderly patients treated with TCF should be closely monitored.

Head and Neck Cancer

Among the 174 and 251 patients who received the induction treatment with docetaxel in combination with cisplatin and fluorouracil (TPF) for SCCHN in the TAX323 and TAX324 studies, 18 (10%) and 32 (13%) of the patients were 65 years of age or older, respectively.

These clinical studies of docetaxel in combination with cisplatin and fluorouracil in patients with SCCHN did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience with this treatment regimen has not identified differences in responses between elderly and younger patients.

Patients with bilirubin >ULN should not receive Docetaxel Injection. Also, patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN should not receive Docetaxel Injection. [see Boxed Warning, Warnings and Precautions (5.2), Clinical Pharmacology (12.3)].

The alcohol content of Docetaxel Injection should be taken into account when given to patients with hepatic impairment [ see Warnings and Precautions (5.11) ].

There is no known antidote for Docetaxel Injection overdosage. In case of overdosage, the patient should be kept in a specialized unit where vital functions can be closely monitored. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken, as needed.

In two reports of overdose, one patient received 150 mg/m and the other received 200 mg/m as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.

In mice, lethality was observed following single intravenous doses that were ≥154 mg/kg (about 4.5 times the human dose of 100 mg/m on a mg/m basis); neurotoxicity associated with paralysis, non-extension of hind limbs, and myelin degeneration was observed in mice at 48 mg/kg (about 1.5 times the human dose of 100 mg/m basis). In male and female rats, lethality was observed at a dose of 20 mg/kg (comparable to the human dose of 100 mg/m on a mg/m basis) and was associated with abnormal mitosis and necrosis of multiple organs.

Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N- tert-butyl ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate. Docetaxel has the following structural formula:

Docetaxel is a white to off-white powder with an empirical formula of C H NO and a molecular weight of 807.88. It is highly lipophilic and practically insoluble in water.

Two-vial formulation (Injection with Diluent)

Docetaxel Injection USP is a clear yellow to brownish-yellow viscous solution. Docetaxel Injection USP is sterile, non-pyrogenic, and is available in single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel anhydrous USP. Each mL contains 40 mg docetaxel anhydrous USP, 60 mg dehydrated alcohol and 1040 mg polysorbate 80. Citric acid (anhydrous) may be used to adjust the pH.

Docetaxel Injection USP requires dilution with Diluent prior to addition to the infusion bag. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The diluent for Docetaxel Injection USP contains 13% polyethylene glycol 400 in water for injection, and is supplied in vials.

One-vial formulation (Injection)

Docetaxel Injection USP is a sterile, non-pyrogenic, pale yellow to brownish-yellow solution at 20 mg/mL concentration.

Each mL contains 20 mg docetaxel anhydrous USP, 4 mg anhydrous citric acid, 520 mg polysorbate 80 and 395 mg dehydrated alcohol solution.

Docetaxel Injection USP is available in single dose and multiple dose vials containing 20 mg (1 mL), 80 mg (4 mL) or 160 mg (8 mL) docetaxel anhydrous USP.

Docetaxel Injection USP requires NO prior dilution with a diluent and is ready to add to the infusion solution.

Absorption: The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20 mg/m to 115 mg/m in phase 1 studies. The area under the curve (AUC) was dose proportional following doses of 70 mg/m to 115 mg/m with infusion times of 1 to 2 hours. Docetaxel's pharmacokinetic profile is consistent with a three-compartment pharmacokinetic model, with half-lives for the α, β, and γ phases of 4 min, 36 min, and 11.1 hr, respectively. Mean total body clearance was 21 L/h/m

Distribution: The initial rapid decline represents distribution to the peripheral compartments and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the peripheral compartment. Mean steady state volume of distribution was 113 L. In vitro studies showed that docetaxel is about 94% protein bound, mainly to α -acid glycoprotein, albumin, and lipoproteins. In three cancer patients, the in vitro binding to plasma proteins was found to be approximately 97%. Dexamethasone does not affect the protein binding of docetaxel.

Metabolism: In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme, and its metabolism may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4 [see Drug Interactions (7)].

Elimination: A study of C-docetaxel was conducted in three cancer patients. Docetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively. About 80% of the radioactivity recovered in feces is excreted during the first 48 hours as 1 major and 3 minor metabolites with very small amounts (< 8%) of unchanged drug.

Effect of Age: A population pharmacokinetic analysis was carried out after docetaxel treatment of 535 patients dosed at 100 mg/m . Pharmacokinetic parameters estimated by this analysis were very close to those estimated from phase 1 studies. The pharmacokinetics of docetaxel were not influenced by age.

Effect of Gender: The population pharmacokinetics analysis described above also indicated that gender did not influence the pharmacokinetics of docetaxel.

Effect of Race: Mean total body clearance for Japanese patients dosed at the range of 10 mg/m to 90 mg/m was similar to that of European/American populations dosed at 100 mg/m , suggesting no significant difference in the elimination of docetaxel in the two populations.

Effect of Ketoconazole: The effect of ketoconazole (a strong CYP3A4 inhibitor) on the pharmacokinetics of docetaxel was investigated in 7 cancer patients. Patients were randomized to receive either docetaxel (100 mg/m intravenous) alone or docetaxel (10 mg/m intravenous) in combination with ketoconazole (200 mg orally once daily for 3 days) in a crossover design with a 3-week washout period. The results of this study indicated that the mean dose-normalized AUC of docetaxel was increased 2.2-fold and its clearance was reduced by 49% when docetaxel was co-administration with ketoconazole [see Dosage and Administration (2.7) and Drug-Drug Interactions (7)]

Effect of Combination Therapies:

Carcinogenicity studies with docetaxel have not been performed.

Docetaxel was clastogenic in the in vitro chromosome aberration test in CHO-K cells and in the in vivo micronucleus test in mice administered doses of 0.39 to 1.56 mg/kg (about 1/60 to 1/15 the recommended human dose on a mg/m basis). Docetaxel was not mutagenic in the Ames test or the CHO/HGPRT gene mutation assays.

Docetaxel did not reduce fertility in rats when administered in multiple intravenous doses of up to 0.3 mg/kg (about 1/50 the recommended human dose on a mg/m basis), but decreased testicular weights were reported. This correlates with findings of a 10-cycle toxicity study (dosing once every 21 days for 6 months) in rats and dogs in which testicular atrophy or degeneration was observed at intravenous doses of 5 mg/kg in rats and 0.375 mg/kg in dogs (about 1/3 and 1/15 the recommended human dose on a mg/m basis, respectively). An increased frequency of dosing in rats produced similar effects at lower dose levels.

The efficacy and safety of another formulation of docetaxel have been evaluated in locally advanced or metastatic breast cancer after failure of previous chemotherapy (alkylating agent-containing regimens or anthracycline-containing regimens).

Randomized Trials

In one randomized trial, patients with a history of prior treatment with an anthracycline containing regimen were assigned to treatment with docetaxel (100 mg/m every 3 weeks) or the combination of mitomycin (12 mg/m every 6 weeks) and vinblastine (6 mg/m every 3 weeks). Two hundred three patients were randomized to docetaxel and 189 to the comparator arm. Most patients had received prior chemotherapy for metastatic disease; only 27 patients on the docetaxel arm and 33 patients on the comparator arm entered the study following relapse after adjuvant therapy. Three-quarters of patients had measurable, visceral metastases. The primary endpoint was time to progression. The following table summarizes the study results (See Table 13).

In a second randomized trial, patients previously treated with an alkylating-containing regimen were assigned to treatment with docetaxel (100 mg/m ) or doxorubicin (75 mg/m ) every 3 weeks. One hundred sixty-one patients were randomized to docetaxel and 165 patients to doxorubicin. Approximately one-half of patients had received prior chemotherapy for metastatic disease, and one-half entered the study following relapse after adjuvant therapy. Three-quarters of patients had measurable, visceral metastases. The primary endpoint was time to progression. The study results are summarized below (See Table 14).

In another multicenter open-label, randomized trial (TAX313), in the treatment of patients with advanced breast cancer who progressed or relapsed after one prior chemotherapy regimen, 527 patients were randomized to receive docetaxel monotherapy 60 mg/m (n=151), 75 mg/m (n=188) or 100 mg/m (n=188). In this trial, 94% of patients had metastatic disease and 79% had received prior anthracycline therapy. Response rate was the primary endpoint. Response rates increased with docetaxel dose: 19.9% for the 60 mg/m group compared to 22.3% for the 75 mg/m and 29.8% for the 100 mg/m group; pair-wise comparison between the 60 mg/m and 100 mg/m groups was statistically significant (p=0.037).

Table 13 - Efficacy of Docetaxel in the Treatment of Breast Cancer Patients Previously Treated with an Anthracycline-Containing Regimen (Intent-to-Treat Analysis)
Efficacy Parameter Docetaxel
(n=203)
Mitomycin/Vinblastine
(n=189)
p-value
Median Survival 11.4 months 8.7 months
Risk Ratio For the risk ratio, a value < 1.00 favors docetaxel., Mortality
(Docetaxel: Control)
0.73 p=0.01
Log Rank
95% CI (Risk Ratio) 0.58 to 0.93
Median Time to Progression 4.3 months 2.5 months
Risk Ratio , Progression
(Docetaxel: Control)
0.75 p=0.01
Log Rank
95% CI (Risk Ratio) 0.61 to 0.94
Overall Response Rate 28.1% 9.5% p<0.0001
Complete Response Rate 3.4% 1.6% Chi Square
Table 14 - Efficacy of Docetaxel in the Treatment of Breast Cancer Patients Previously Treated with an Alkylating-Containing Regimen (Intent-to-Treat Analysis)
Efficacy Parameter Docetaxel
(n=161)
Doxorubicin
(n=165)
p-value
Median Survival 14.7 months 14.3 months
Risk Ratio For the risk ratio, a value < 1.00 favors docetaxel., Mortality
(Docetaxel: Control)
0.89 p=0.39
Log Rank
95% CI (Risk Ratio) 0.68 to 1.16
Median Time to Progression 6.5 months 5.3 months
Risk Ratio , Progression
(Docetaxel: Control)
0.93 p=0.45
Log Rank
95% CI (Risk Ratio) 0.71 to 1.16
Overall Response Rate 45.3% 29.7% p=0.004
Complete Response Rate 6.8% 4.2% Chi Square

Single Arm Studies

Docetaxel at a dose of 100 mg/m was studied in six single arm studies involving a total of 309 patients with metastatic breast cancer in whom previous chemotherapy had failed. Among these, 190 patients had anthracycline-resistant breast cancer, defined as progression during an anthracycline-containing chemotherapy regimen for metastatic disease, or relapse during an anthracycline-containing adjuvant regimen. In anthracycline-resistant patients, the overall response rate was 37.9% (72/190; 95% C.I.: 31.0 to 44.8) and the complete response rate was 2.1%.

Docetaxel was also studied in three single arm Japanese studies at a dose of 60 mg/m , in 174 patients who had received prior chemotherapy for locally advanced or metastatic breast cancer. Among 26 patients whose best response to an anthracycline had been progression, the response rate was 34.6% (95% C.I.: 17.2 to 55.7), similar to the response rate in single arm studies of 100 mg/m .

A multicenter, open-label, randomized trial (TAX316) evaluated the efficacy and safety of another formulation of docetaxel for the adjuvant treatment of patients with axillary-node-positive breast cancer and no evidence of distant metastatic disease. After stratification according to the number of positive lymph nodes (1 to 3, 4+), 1491 patients were randomized to receive either docetaxel 75 mg/m administered 1-hour after doxorubicin 50 mg/m and cyclophosphamide 500 mg/m (TAC arm), or doxorubicin 50 mg/m followed by fluorouracil 500 mg/m and cyclosphosphamide 500 mg/m (FAC arm). Both regimens were administered every 3 weeks for 6 cycles.

Docetaxel was administered as a 1-hour infusion; all other drugs were given as intravenous bolus on day 1. In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years. Adjuvant radiation therapy was prescribed according to guidelines in place at participating institutions and was given to 69% of patients who received TAC and 72% of patients who received FAC.

Results from a second interim analysis (median follow-up 55 months) are as follows: In study TAX316, the docetaxel-containing combination regimen TAC showed significantly longer disease-free survival (DFS) than FAC (hazard ratio=0.74; 2-sided 95% CI=0.60, 0.92, stratified log rank p=0.0047). The primary endpoint, disease-free survival, included local and distant recurrences, contralateral breast cancer and deaths from any cause. The overall reduction in risk of relapse was 25.7% for TAC-treated patients. (See Figure 1).

Figure 1 - TAX316 Disease Free Survival K-M curve

Figure 2 - TAX316 Overall Survival K-M curve

The following table describes the results of subgroup analyses for DFS and OS (See Table 15).

Table 15 - Subset Analyses-Adjuvant Breast Cancer Study
Disease Free Survival Overall Survival
Patient subset Number of patients Hazard ratio a hazard ratio of < 1 indicates that TAC is associated with a longer disease free survival or overall survival compared to FAC. 95% CI Hazard ratio 95% CI
No. of positive nodes
Overall 744 0.74 (0.60, 0.92) 0.69 (0.53, 0.90)
1 to 3 467 0.64 (0.47, 0.87) 0.45 (0.29, 0.70)
4+ 277 0.84 (0.63, 1.12) 0.93 (0.66, 1.32)
Receptor status
Positive 566 0.76 (0.59, 0.98) 0.69 (0.48, 0.99)
Negative 178 0.68 (0.48, 0.97) 0.66 (0.44, 0.98)

Monotherapy with docetaxel for NSCLC Previously Treated with Platinum Based Chemotherapy

Two randomized, controlled trials established that a docetaxel dose of 75 mg/m was tolerable and yielded a favorable outcome in patients previously treated with platinum-based chemotherapy (see below). Docetaxel at a dose of 100 mg/m , however, was associated with unacceptable hematologic toxicity, infections, and treatment-related mortality and this dose should not be used [see Boxed Warning, Dosage and Administration (2.7), Warnings and Precautions (5.3)].

One trial (TAX317), randomized patients with locally advanced or metastatic non-small cell lung cancer, a history of prior platinum-based chemotherapy, no history of taxane exposure, and an ECOG performance status ≤2 to docetaxel or best supportive care. The primary endpoint of the study was survival. Patients were initially randomized to docetaxel 100 mg/m or best supportive care, but early toxic deaths at this dose led to a dose reduction to docetaxel 75 mg/m . A total of 104 patients were randomized in this amended study to either docetaxel 75 mg/m or best supportive care.

In a second randomized trial (TAX320), 373 patients with locally advanced or metastatic non small cell lung cancer, a history of prior platinum-based chemotherapy, and an ECOG performance status ≤2 were randomized to docetaxel 75 mg/m , docetaxel 100 mg/m and a treatment in which the investigator chose either vinorelbine 30 mg/m days 1, 8, and 15 repeated every 3 weeks or ifosfamide 2 g/m days 1 to 3 repeated every 3 weeks. Forty percent of the patients in this study had a history of prior paclitaxel exposure. The primary endpoint was survival in both trials. The efficacy data for the docetaxel 75 mg/m arm and the comparator arms are summarized in Table 16 and Figures 3 and 4 showing the survival curves for the two studies.

Only one of the two trials (TAX317) showed a clear effect on survival, the primary endpoint; that trial also showed an increased rate of survival to one year. In the second study (TAX320) the rate of survival at one year favored docetaxel 75 mg/m .

Figure 3 - TAX317 Survival K-M Curves - Docetaxel 75 mg/m vs. Best Supportive Care

Figure 4 - TAX320 Survival K-M Curves - Docetaxel 75 mg/m vs. Vinorelbine or Ifosfamide Control

Patients treated with docetaxel at a dose of 75 mg/m experienced no deterioration in performance status and body weight relative to the comparator arms used in these trials.

Table 16 - Efficacy of Docetaxel in the Treatment of Non-Small Cell Lung Cancer Patients Previously Treated with a Platinum-Based Chemotherapy Regimen (Intent-to-Treat Analysis)
TAX317 TAX320
Docetaxel
75 mg/m 2
n=55
Best Supportive Care
n=49
Docetaxel
75 mg/m 2
n=125
Control (V/I Vinorelbine/Ifosfamide )
n=123
Overall Survival
Log-rank Test p=0.01 p=0.13
Risk Ratio a value < 1.00 favors docetaxel, Mortality
(Docetaxel: Control) 0.56 0.82
95% CI (Risk Ratio) (0.35, 0.88) (0.63, 1.06)
Median Survival 7.5 months p≤0.05 4.6 months 5.7 months 5.6 months
95% CI (5.5, 12.8) (3.7, 6.1) (5.1, 7.1) (4.4, 7.9)
% 1-year Survival 37% uncorrected for multiple comparisons 12% 30% 20%
95% CI (24, 50) (2, 23) (22, 39) (13, 27)
Time to Progression 12.3 weeks 7.0 weeks 8.3 weeks 7.6 weeks
95% CI (9.0, 18.3) (6.0, 9.3) (7.0, 11.7) (6.7, 10.1)
Response Rate 5.5% Not Applicable 5.7% 0.8%
95% CI (1.1, 15.1) (2.3, 11.3) (0.0, 4.5)

Combination Therapy with docetaxel for Chemotherapy-Naïve NSCLC

In a randomized controlled trial (TAX326), 1218 patients with unresectable stage IIIB or IV NSCLC and no prior chemotherapy were randomized to receive one of three treatments: docetaxel 75 mg/m as a 1 hour infusion immediately followed by cisplatin 75 mg/m over 30 to 60 minutes every 3 weeks; vinorelbine 25 mg/m administered over 6 to 10 minutes on days 1, 8, 15, 22 followed by cisplatin 100 mg/m administered on day 1 of cycles repeated every 4 weeks; or a combination of docetaxel and carboplatin.

The primary efficacy endpoint was overall survival. Treatment with docetaxel+cisplatin did not result in a statistically significantly superior survival compared to vinorelbine+cisplatin (see table below). The 95% confidence interval of the hazard ratio (adjusted for interim analysis and multiple comparisons) shows that the addition of docetaxel to cisplatin results in an outcome ranging from a 6% inferior to a 26% superior survival compared to the addition of vinorelbine to cisplatin. The results of a further statistical analysis showed that at least (the lower bound of the 95% confidence interval) 62% of the known survival effect of vinorelbine when added to cisplatin (about a 2-month increase in median survival; Wozniak et al. JCO, 1998) was maintained. The efficacy data for the docetaxel+cisplatin arm and the comparator arm are summarized in Table 17.

The second comparison in the same three-arm study, vinorelbine+cisplatin versus docetaxel+carboplatin, did not demonstrate superior survival associated with the docetaxel arm (Kaplan-Meier estimate of median survival was 9.1 months for docetaxel +carboplatin compared to 10.0 months on the vinorelbine+cisplatin arm) and the docetaxel+carboplatin arm did not demonstrate preservation of at least 50% of the survival effect of vinorelbine added to cisplatin. Secondary endpoints evaluated in the trial included objective response and time to progression. There was no statistically significant difference between docetaxel+cisplatin and vinorelbine+cisplatin with respect to objective response and time to progression (see Table 18).

Table 17 - Survival Analysis of Docetaxel in Combination Therapy for Chemotherapy Naïve NSCLC
Comparison Docetaxel + Cisplatin
n=408
Vinorelbine + Cisplatin
n=405
Kaplan-Meier Estimate of Median Survival 10.9 months 10.0 months
p-value From the superiority test (stratified log rank) comparing docetaxel + cisplatin to vinorelbine+cisplatin 0.122
Estimated Hazard Ratio Hazard ratio of docetaxel + cisplatin vs. vinorelbine + cisplatin. A hazard ratio of < 1 indicates that docetaxel + cisplatin is associated with a longer survival. 0.88
Adjusted 95% CI Adjusted for interim analysis and multiple comparisons. (0.74, 1.06)
Table 18 - Response and TTP Analysis of Docetaxel in Combination Therapy for Chemotherapy-Naïve NSCLC
Endpoint Docetaxel + Cisplatin Vinorelbine + Cisplatin p-value
Objective Response Rate 31.6% 24.4% Not Significant
(95% CI) Adjusted for multiple comparisons. (26.5%, 36.8%) (19.8%, 29.2%)
Median Time to Progression Kaplan-Meier estimates. 21.4 weeks
(19.3, 24.6)
22.1 weeks
(18.1, 25.6)
Not Significant
(95% CI)

The safety and efficacy of another formulation of docetaxel in combination with prednisone in patients with androgen independent (hormone refractory) metastatic prostate cancer were evaluated in a randomized multicenter active control trial. A total of 1006 patients with Karnofsky Performance Status (KPS) ≥60 were randomized to the following treatment groups:

All 3 regimens were administered in combination with prednisone 5 mg twice daily, continuously.

In the docetaxel every three week arm, a statistically significant overall survival advantage was demonstrated compared to mitoxantrone. In the docetaxel weekly arm, no overall survival advantage was demonstrated compared to the mitoxantrone control arm. Efficacy results for the docetaxel every 3 week arm versus the control arm are summarized in Table 19 and Figure 5.

Figure 5 - TAX327 Survival K-M Curves

Table 19 - Efficacy of Docetaxel in the Treatment of Patients with Androgen Independent (Hormone Refractory) Metastatic Prostate Cancer (Intent-to-Treat Analysis)
Docetaxel + Prednisone every 3 weeks Mitoxantrone + Prednisone every 3 weeks
Number of patients 335 337
Median survival (months) 18.9 16.5
95% CI (17.0 to 21.2) (14.4 to 18.6)
Hazard ratio 0.761 --
95% CI (0.619 to 0.936) --
p-value Stratified log rank test. Threshold for statistical significance = 0.0175 because of 3 arms. 0.0094 --

A multicenter, open-label, randomized trial was conducted to evaluate the safety and efficacy of another formulation of docetaxel for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for advanced disease. A total of 445 patients with KPS >70 were treated with either docetaxel (T) (75 mg/m on day 1) in combination with cisplatin (C) (75 mg/m on day 1) and fluorouracil (F) (750 mg/m per day for 5 days) or cisplatin (100 mg/m on day 1) and fluorouracil (1000 mg/m per day for 5 days). The length of a treatment cycle was 3 weeks for the TCF arm and 4 weeks for the CF arm. The demographic characteristics were balanced between the two treatment arms. The median age was 55 years, 71% were male, 71% were Caucasian, 24% were 65 years of age or older, 19% had a prior curative surgery and 12% had palliative surgery. The median number of cycles administered per patient was 6 (with a range of 1 to 16) for the TCF arm compared to 4 (with a range of 1 to 12) for the CF arm. Time to progression (TTP) was the primary endpoint and was defined as time from randomization to disease progression or death from any cause within 12 weeks of the last evaluable tumor assessment or within 12 weeks of the first infusion of study drugs for patients with no evaluable tumor assessment after randomization. The hazard ratio (HR) for TTP was 1.47 (CF/TCF, 95% CI: 1.19 to 1.83) with a significantly longer TTP (p=0.0004) in the TCF arm. Approximately 75% of patients had died at the time of this analysis. Overall survival was significantly longer (p=0.0201) in the TCF arm with a HR of 1.29 (95% CI: 1.04 to 1.61). Efficacy results are summarized in Table 20 and Figures 6 and 7.

Subgroup analyses were consistent with the overall results across age, gender and race.

Figure 6 - Gastric Cancer Study (TAX325) Time to Progression K-M Curve

Figure 7 - Gastric Cancer Study (TAX325) Survival K-M Curve

Table 20 - Efficacy of Docetaxel in the treatment of patients with gastric adenocarcinoma
Endpoint TCF
n=221
CF
n=224
Median TTP (months) 5.6 3.7
(95%CI) (4.86 to 5.91) (3.45 to 4.47)
Hazard ratio For the hazard ratio (TCF/CF), values < 1.00 favor the docetaxel arm. 0.68
(95%CI) (0.55 to 0.84)
Unstratified log-rank testp-value 0.0004
Median survival (months) 9.2 8.6
(95%CI) (8.38 to 10.58) (7.16 to 9.46)
Hazard ratio 0.77
(95%CI) (0.62 to 0.96)
p-value 0.0201
Overall Response Rate (CR+PR) (%) 36.7 25.4
p-value 0.0106

Induction chemotherapy followed by radiotherapy (TAX323)

The safety and efficacy of another formulation of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a multicenter, open-label, randomized trial (TAX323). In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance status 0 or 1, were randomized to one of two treatment arms. Patients on the docetaxel arm received docetaxel (T) 75 mg/m followed by cisplatin (P) 75 mg/m on Day 1, followed by fluorouracil (F) 750 mg/m per day as a continuous infusion on Days 1 to 5. The cycles were repeated every three weeks for 4 cycles. Patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines (TPF/RT). Patients on the comparator arm received cisplatin (P) 100 mg/m on Day 1, followed by fluorouracil (F) 1000 mg/m /day as a continuous infusion on Days 1 to 5. The cycles were repeated every three weeks for 4 cycles. Patients whose disease did not progress received RT according to institutional guidelines (PF/RT). At the end of chemotherapy, with a minimal interval of 4 weeks and a maximal interval of 7 weeks, patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines. Locoregional therapy with radiation was delivered either with a conventional fraction regimen (1.8 Gy to 2.0 Gy once a day, 5 days per week for a total dose of 66 to 70 Gy) or with an accelerated/hyperfractionated regimen (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week, for a total dose of 70 to 74 Gy, respectively). Surgical resection was allowed following chemotherapy, before or after radiotherapy.

Figure 8 - TAX323 Progression-Free Survival K-M Curve

Figure 9 - TAX323 Overall Survival K-M Curve

Table 21 - Efficacy of Docetaxel in the induction treatment of patients with inoperable locally advanced SCCHN (Intent-to-Treat Analysis)
ENDPOINT Docetaxel+
Cisplatin+
Fluorouracil
n=177
Cisplatin+
Fluorouracil
n=181
A Hazard ratio of < 1 favors Docetaxel+Cisplatin+Fluorouracil
Median progression free survival (months)
(95%CI)
11.4
(10.1 to 14.0)
8.3
(7.4 to 9.1)
Adjusted Hazard ratio
(95%CI)
Stratified log-rank test based on primary tumor sitep-value
0.71
(0.56 to 0.91)
0.0077
Median survival (months)
(95%CI)
18.6
(15.7 to 24.0)
14.2
(11.5 to 18.7)
Hazard ratio
(95%CI)
Stratified log-rank test, not adjusted for multiple comparisonsp-value
0.71
(0.56 to 0.90)
0.0055
Best overall response (CR + PR) to
chemotherapy (%)
(95%CI)
67.8
(60.4 to 74.6)
53.6
(46.0 to 61.0)
Chi square test, not adjusted for multiple comparisonsp-value 0.006
Best overall response (CR + PR) to study
treatment [chemotherapy +/- radiotherapy] (%)
(95%CI)
72.3
(65.1 to 78.8)
58.6
(51.0 to 65.8)
p-value 0.006

Induction chemotherapy followed by chemoradiotherapy (TAX324)

The safety and efficacy of another formulation of docetaxel in the induction treatment of patients with locally advanced (unresectable, low surgical cure, or organ preservation) SCCHN was evaluated in a randomized, multicenter open-label trial (TAX324). In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two treatment arms. Patients on the docetaxel arm received docetaxel (T) 75 mg/m by intravenous infusion on day 1 followed by cisplatin (P) 100 mg/m administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of fluorouracil (F) 1000 mg/m /day from day 1 to day 4. The cycles were repeated every 3 weeks for 3 cycles. Patients on the comparator arm received cisplatin (P) 100 mg/m as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of fluorouracil (F) 1000 mg/m /day from day 1 to day 5. The cycles were repeated every 3 weeks for 3 cycles.

The primary efficacy endpoint, overall survival (OS), was significantly longer (log-rank test, p=0.0058) with the docetaxel-containing regimen compared to PF [median OS: 70.6 versus 30.1 months respectively, hazard ratio (HR)=0.70, 95% confidence interval (CI)= 0.54 to 0.90]. Overall survival results are presented in Table 22 and Figure 10.

Figure 10 - TAX324 Overall Survival K-M Curve

Table 22 - Efficacy of Docetaxel in the induction treatment of patients with locally advanced SCCHN (Intent-to-Treat Analysis)
ENDPOINT Docetaxel +
Cisplatin+ Fluorouracil
n=255
Cisplatin+
Fluorouracil
n=246
A Hazard ratio of < 1 favors docetaxel + cisplatin + fluorouracil
NE - not estimable
Median overall survival (months)
(95% CI)
70.6
(49.0 to NE)
30.1
(20.9 to 51.5)
Hazard ratio:
(95% CI)
un-adjusted log-rank test p-value
0.70
(0.54 to 0.90)
0.0058

One-vial formulation (Injection)

Docetaxel Injection is supplied in single dose and multiple dose vials as a sterile, pyrogen-free, non-aqueous solution.

Docetaxel Injection 80 mg/4 mL: The vial is in one carton. NDC 63739-971-17

Docetaxel Injection 20 mg/mL: The vial is in one carton. NDC 63739-932-11

Two-vial formulation (Injection with Diluent)

One-vial formulation (Injection)

After initial puncture, Docetaxel Injection multiple dose vials are stable for 28 days when stored at room temperature, with protection from light.

Follow procedures for proper handling and disposal of anticancer drugs.

See FDA-Approved Patient Labeling

Manufactured by:

Intas Pharmaceuticals Limited,

Ahmedabad-380 009, India.

Distributed by:

McKesson Packaging Services,

A business unit of McKesson Corporation.

7101 Weddington Rd, Concord, NC 28027

Toll Free: 1-888-243-4363

10 10580 2 665816

Revised July 2016

INP058

Patient Information
DOCETAXEL (doe-se-TAKS-el) injection
for intravenous use The chance of death in people who receive Docetaxel Injection is higher if you: have liver problems receive high doses of Docetaxel Injection have non-small cell lung cancer and have been treated with chemotherapy medicines that contain platinum Docetaxel Injection can affect your blood cells.Your doctor should do routine blood tests during treatment with Docetaxel Injection. This will include regular checks of your white blood cell counts. If your white blood cells are too low, your doctor may not treat you with Docetaxel Injection until you have enough white blood cells. People with low white blood counts can develop life-threatening infections. The earliest sign of infection may be fever. Follow your doctor’s instructions for how often to take your temperature while taking Docetaxel Injection. Call your doctor right away if you have a fever. Serious allergic reactions can happen in people who take Docetaxel Injection. Serious allergic reactions are medical emergencies that can lead to death and must be treated right away.
Tell your doctor right away if you have any of these signs of a serious allergic reaction: trouble breathing sudden swelling of your face, lips, tongue, throat, or trouble swallowing hives (raised bumps), rash, or redness all over your body Your body may hold too much fluid (severe fluid retention) during treatment with Docetaxel Injection. This can be life threatening. To decrease the chance of this happening, you must take another medicine, a corticosteroid, before each Docetaxel Injection treatment. You must take the corticosteroid exactly as your doctor tells you. Tell your doctor or nurse before your Docetaxel Injection treatment if you forget to take corticosteroid dose or do not take it as your doctor tells you. What is Docetaxel Injection?
Docetaxel Injection is a prescription anti-cancer medicine used to treat certain people with: breast cancer non-small cell lung cancer prostate cancerstomach cancer head and neck cancer It is not known if Docetaxel Injection is effective in children.
Do not receive Docetaxel Injection if you:
have had a severe allergic reaction to:
‑ docetaxel, the active ingredient in Docetaxel Injection, or
‑ any other medicines that contain polysorbate 80. Ask your doctor or pharmacist if you are not sure. See “ What is the most important information I should know about Docetaxel Injection? ” for the signs and symptoms of a severe allergic reaction. have a low white blood cell count. What should I tell my doctor before receiving Docetaxel Injection?
Before you receive Docetaxel Injection, tell your doctor if you:
are allergic to any medicines. See “ Who should not receive Docetaxel Injection?” Also, see the end of this leaflet for a complete list of the ingredients in Docetaxel Injection. have liver problems have any other medical conditions are pregnant or plan to become pregnant. Docetaxel Injection can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if Docetaxel Injection passes into your breast milk. You and your doctor should decide if you will receive Docetaxel Injection or breastfeed. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Docetaxel Injection may affect the way other medicines work, and other medicines may affect the way Docetaxel Injection works.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. Docetaxel Injection will be given to you as an intravenous (IV) injection into your vein, usually over 1 hour. Docetaxel Injection is usually given every 3 weeks. Your doctor will decide how long you will receive treatment with Docetaxel Injection. Your doctor will check your blood cell counts and other blood tests during your treatment with Docetaxel Injection to check for side effects of Docetaxel Injection. Your doctor may stop your treatment, change the timing of your treatment, or change the dose of your treatment if you have certain side effects while receiving Docetaxel Injection.See “ What is the most important information I should know about Docetaxel Injection?” Acute Myeloid Leukemia (AML), a type of blood cancer, can happen in people who take Docetaxel Injection along with certain other medicines. Other Blood Disorders. Changes in blood counts due to leukemia and other blood disorders may occur years after treatment with Docetaxel Injection. Skin Reactions including redness and swelling of your arms and legs with peeling of your skin. Neurologic Symptoms including numbness, tingling, or burning in your hands and feet. Vision Problems including blurred vision or loss of vision. Docetaxel Injection contains alcohol. The alcohol content in Docetaxel Injection may impair your ability to drive or use machinery right after receiving Docetaxel Injection. Consider whether you should drive, operate machinery or do other dangerous activities right after you receive Docetaxel Injection treatment. The most common side effects of Docetaxel Injection include:changes in your sense of taste feeling short of breath constipation decreased appetite changes in your fingernails or toenails swelling of your hands, face or feet feeling weak or tired joint and muscle pain nausea and vomiting diarrheamouth or lips sores hair loss, in most cases normal hair growth should return. In some cases (frequency not known) permanent hair loss has been observed. rash redness of the eye, excess tearing skin reactions at the site of Docetaxel Injection administration such as increased skin pigmentation, redness, tenderness, swelling, warmth or dryness of the skin tissue damage if Docetaxel Injection leaks out of the vein into the tissues Tell your doctor if you have any side effect that bothers you or does not go away.
These are not all the possible side effects of Docetaxel Injection. For more information ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about Docetaxel Injection
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. This Patient Information leaflet summarizes the most important information about Docetaxel Injection. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Docetaxel Injection that is written for health professionals.
This Patient Information has been approved by the U.S. Food and Drug Administration.
Revised: July 2016
   
Read this Patient Information before you receive your first treatment with Docetaxel Injection and each time before you are treated. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
What is the most important information I should know about Docetaxel Injection?
Docetaxel Injection can cause serious side effects, including death.
1.1. 2. 3. 2. 3.4. 5. 6. 4.
 
 
Who should not receive Docetaxel Injection?
  1.   2.
  1. 2. 3. 4. 5.
 
How will I receive Docetaxel Injection?
What are the possible side effects of Docetaxel Injection?
Docetaxel Injection may cause serious side effects including death.
 
 
What are the ingredients in Docetaxel Injection? Two-vial formulation (Injection with Diluent) Active ingredient: docetaxel anhydrous USP Inactive ingredients: dehydrated alcohol, polysorbate 80, anhydrous citric acid and polyethylene glycol 400 One-vial formulation (Injection) Active ingredient: docetaxel anhydrous USP Inactive ingredients: anhydrous citric acid, polysorbate 80 and dehydrated alcohol
Every three-week injection of Docetaxel Injection for breast, non-small cell lung and stomach, and head and neck cancers Take your oral corticosteroid medicine as your doctor tells you. Oral corticosteroid dosing: Day 1 Date:________ Time:_____ AM______ PM Day 2 Date:________ Time:_____ AM______ PM (Docetaxel Injection Treatment Day) Day 3 Date:________ Time:_____ AM______ PM
Every three-week injection of Docetaxel Injection for prostate cancer Take your oral corticosteroid medicine as your doctor tells you. Oral corticosteroid dosing: Date:________ Time:_____ Date:________ Time:_____ (Docetaxel Injection Treatment Day)           Time:_____

Manufacturer

McKesson Packaging Services a business unit of McKesson Corporation

Active Ingredients

Source

Drugs and Medications [49 Associated Drugs and Medications listed on BioPortfolio]

Docetaxel [sandoz inc.]

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION. DOCETAXEL INJECTION, for intrave...

Docetaxel [accord healthcare inc.]

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION DOCETAXEL injection, for intraven...

Docetaxel [ingenus pharmaceuticals, llc]

These highlights do not include all the information needed to use DOCETAXEL INJECTION, safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, For intrave...

Docetaxel anhydrous [cipla usa inc.]

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intraven...

Docetaxel [sandoz inc.]

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION. DOCETAXEL INJECTION, for intrave...

Clinical Trials [1155 Associated Clinical Trials listed on BioPortfolio]

Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide

The purpose of this study is to adjust the amount of docetaxel participants receive based on the level of docetaxel measured in their blood. This method of dose adjustment is called pharma...

Gemcitabine and Docetaxel With Or Without Bevacizumab in Leiomyosarcoma, Malignant Fibrous Histiocytoma and Angiosarcoma

The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sa...

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.

Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer

This study is an open-label, single center, and a single arm phase II study to evaluate the clinical response and safety of perioperative S-1 plus docetaxel. Perioperative chemotherapy is ...

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.

PubMed Articles [109 Associated PubMed Articles listed on BioPortfolio]

Preparation, characterization and in vitro activity of a docetaxel-albumin conjugate.

Docetaxel is one of the most effective anticancer drugs. However, the current formulation of docetaxel contains Tween 80 and ethanol as the solvent, which can cause severe side effects. Consequently, ...

A new method for the determination of total and released docetaxel from docetaxel-entrapped core-crosslinked polymeric micelles (CriPec®) by LC-MS/MS and its clinical application in plasma and tissues in patients with various tumours.

A sensitive, high-performance liquid chromatographic method was developed and validated, for determination of docetaxel from docetaxel-entrapped core-crosslinked polymeric micelles (CriPec®) in human...

Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study.

Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the cytochrome P450 iso-enzyme CYP3A4, which is the main...

Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9 led to increase docetaxel sensitivity via suppressing the p21 expression.

Chemotherapy with docetaxel remains as the effective therapy to suppress castration resistant prostate cancer (CRPC) in some patients. However, most chemotherapy with docetaxel eventually fails with t...

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

Docetaxel improves survival in patients with metastatic prostate cancer (PC). This randomized phase II trial aimed to assess the activity of weekly docetaxel with radiotherapy (RT) plus androgen depri...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record